血清miR-223-3p的增加表明支气管支气管病的发病,严重发展和不良预后:一项回顾性研究
Jia Fang1, Yao Xu2, Chenghui Lin1
1Respiratory Medicine Center, The First Dongguan Affiliated Hospital of Guangdong Medical University, No. 42, Jiaoping Road, Tangxia Town, Dongguan, 523710, China.
BMC pulmonary medicine
|July 22, 2024
概括
血清miR-223-3p是支气管切除 (BE) 的一个有前途的生物标志物. 升高的水平表明疾病发病,严重程度,并预测BE患者的预后不佳,有助于临床诊断和监测.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 肺部病理学 肺部病理学
背景情况:
- miR-223-3p与Pseudomonas aeruginosa在支气管炎 (BE) 中的殖民活动有关.
- 它在BE诊断和监测中的临床实用性仍未得到充分研究.
- 这项研究研究了miR-223-3p作为BE的潜在生物标志物.
研究的目的:
- 评估血清miR-223-3p作为BE的诊断生物标志物.
- 评估miR-223-3p与BE严重程度和炎症的相关性.
- 在BE患者中确定miR-223-3p的预后值.
主要方法:
- 在健康个体 (n=101) 和BE患者 (n=133) 中比较血清miR-223-3p水平.
- 评估了miR-223-3p与炎症标志物 (CRP,PCT,IL-6,NLR) 和BE严重性得分 (BSI,FACED) 的相关性.
- 使用后勤回归来预测3年后期的预后.
主要成果:
- 在BE患者中,血清miR-223-3p显著上调,使其与健康对照区分开来.
- miR-223-3p与炎症标志物和BE严重性得分正相关.
- 较高的miR-223-3p水平预测了BE患者的不良预后.
结论:
- 血清miR-223-3p作为一种宝贵的生物标志物,用于BE的发病.
- miR-223-3p水平反映了BE的疾病严重程度和炎症.
- 血清miR-223-3p的升高是支气管切除症预后不佳的指标.
相关概念视频
Pleural Effusion II: Symptoms and Management
162
Pleural Effusion Overview
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
A pleural effusion is the abnormal collection of fluid between the parietal and visceral pleura layers of tissue that form the lining of the lungs and chest cavity. It can occur independently or due to surrounding parenchymal diseases, such as infection, malignancy, or inflammatory conditions.
Clinical Manifestations:
162
Pneumonia III: Complications and Assessment
195
Pneumonia poses the potential for numerous complications that warrant consideration. These complications include the following:
195
COPD: Management Using Bronchodilators and Corticosteroids
193
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
193
Cystic Fibrosis: Management
154
Cystic fibrosis (CF) is an autosomal recessive disorder that predominantly affects individuals of Northern European descent, occurring at a rate of 1 in 3500. It is caused by a genetic mutation in a gene on chromosome 7, most commonly the ΔF508 mutation, that codes for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. This results in thicker mucus secretions and obstruction pathologies in multiple organs, including the lungs and sinuses.
Sinus disease and chronic...
Sinus disease and chronic...
154
Cystic Fibrosis: Pathogenesis
202
Cystic fibrosis (CF), an autosomal recessive disorder, significantly affects the function of exocrine glands. This genetically inherited disease is characterized by the production of thick and sticky mucus, which can severely affect various organs and systems in the body.
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
CF is primarily caused by a genetic mutation in a chromosome 7 gene coding for the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common gene mutation leading to CF is the ΔF508 mutation,...
202


